Larvol Delta - First-Participant-Dosed-in-Europe-as-Cognition-Therapeutics-Expand-Phase-2-Alzheimer39s-Disease-Clinical-Trial-of-Oral-CT1812

Elayta (CT1812) - Cognition Therap

https://www.globenewswire.com/news-release/2022/12/15/2574547/0/en/First-Participant-Dosed-in-Europe-as-Cognition-Therapeutics-Expand-Phase-2-Alzheimer-s-Disease-Clinical-Trial-of-Oral-CT1812.html

Dec 15, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next